NCT04535999View on ClinicalTrials.gov

Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)

PHASE4CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 7, 2022

Primary Completion Date

May 30, 2025

Study Completion Date

May 30, 2025

Conditions
Psoriasis
Interventions
DRUG

Secukinumab Auto-Injector

300 mg- Every 4 weeks after loading dose (Loading Dose-300 mg once weekly for 5 weeks)

Trial Locations (1)

19104

Hospital at the University of Pennsylvania, Philadelphia

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of Pennsylvania

OTHER